Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2811-2815

  Pescovitz, M D ^a   Rabkin, J ^a   Merion, R M ^a   Paya, C V ^a   Pirsch, J ^a   Freeman, R B ^a   O'Grady, J ^a   Robinson, C ^a   To, Z ^a   Wren, K ^a   Banken, L ^a   Buhles, W ^a   Brown, F ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; VALGANCICLOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYTOMEGALOVIRUS INFECTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTIVIRAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HUMANS; INTESTINAL ABSORPTION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; STIMULATION, CHEMICAL;

EID: 0033807143     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2811-2815.2000     Document Type: Article

References (25)

1. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers
2. An HPLC method for the determination of diastereomeric prodrug RS-79070-004 in human plasma
3. A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum
4. Prediction of creatinine clearance from serum creatinine
5. Cytomegalovirus (CMV) resistance in patients with CMV retinitis and AIDS treated with oral or intravenous ganciclovir
6. Resistance of human cytomegalovirus to antiviral drugs
7. Prophylactic oral ganciclovir after renal transplantation - Dosing and pharmacokinetics
8. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: Correlation with disease
9. Valacyclovir: A substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2
10. Efficacy and safety of oral ganciclovir in the prevention of CMV disease in liver transplant recipients: Results of a multicenter, multinational clinical trial
11. Progress in the clinical management of herpesvirus infections
12. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects
13. Cytomegalovirus infection following liver transplantation: Review of the literature
14. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation
15. Ganciclovir: An update on its use in the prevention of cytomegalovirus infection and disease in transplant recipients
16. Cytomegalovirus prophylaxis in solid organ transplant recipients
17. Intraoperative hypothermia is an independent risk factor for early cytomegalovirus infection in liver transplant recipients
18. Oral ganciclovir in pediatric transplant recipients: A pharmacokinetic study
19. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function
20. Changes in the level of CMV antigenemia (pp65) in liver transplant recipients receiving oral ganciclovir as CMV prophylaxis
21. Carrier-mediated intestinal absorption of valacyclovir, the L-valyl ester prodrug of acyclovir. 1. Interactions with peptides, organic anions and organic cations in rats
22. Histopathologic findings from 2-year protocol biopsies from a U.S multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group
23. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis
24. Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: A post hoc analysis of a randomized, placebo-controlled study
25. Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients